| Name | Title | Contact Details |
|---|
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin`s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.
Founded in 2012 by international bestselling authors, work-life balance experts, and holistic healthcare providers, Dr. Dave Braun and Dr. Troy Amdahl, Oola provides a simple and easy-to-follow lifestyle framework designed to lead you, step by step, to a life of less stress, more personal growth, and a clearer path toward living your unique purpose. The concept originally ideated in 1997 as Dr. Braun and Dr. Amdahl worked to better themselves in the seven key areas of life -- Fitness, Finance, Family, Field (career), Faith, Friends, and Fun. Since then, the Oola lifestyle has become a global phenomenon, with over a million followers in 40 countries actively creating their best lives. In 2021, Oola announced an affordable personal development eLearning platform to add to their offerings. Expected to launch in Summer 2021, the new platform will accelerate Oola`s goal of impacting one billion lives in seven years.
Opus Healthcare Solutions is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Solace Pediatric Healthcare is a leading provider of pediatric occupational, physical, speech and feeding therapy services in the state of Colorado. They offer in-home and telehealth therapy services for infants and children with developmental delays o...
Ascendis Pharma is focused on creating drug candidates that are improved versions of existing drugs, yielding more effective, lower-risk drugs with new patent life. Our proprietary TransCon platform is the leading, most versatile transient conjugation technology and is utilized to create clinically superior prodrugs in therapeutic areas characterized by high unmet medical need. TransCon technology creates novel long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. Ascendis Pharma has a diversified and balanced high-value pipeline, including internal programs and partnerships together with market leaders on their key projects.